Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 152

Sort by

Sort Order Select

Journal Articles

Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial

Blood blood.2025031313.

https://doi.org/10.1182/blood.2025031313

Published: 2025

Includes: Supplemental data

Journal Articles

Time from AML diagnosis to HCT and pre-HCT FLT3 inhibition impact pre-transplant MRD and benefit from post-HCT gilteritinib

Blood (2025) 146 (Supplement 1): 1058.

https://doi.org/10.1182/blood-2025-1058

Published: 2025

Journal Articles

Effect of FLT3 maintenance in older FLT3-ITD+ adults undergoing allogeneic HCT. a post hoc analysis of BMT CTN 1506

Blood (2025) 146 (Supplement 1): 170.

https://doi.org/10.1182/blood-2025-170

Published: 2025

Journal Articles

Ruxolitinib for refractory immune effector cell enterocolitis following ciltacabtagene autoleucel CAR T-cell therapy for multiple myeloma

Blood (2025) 146 (Supplement 1): 2392.

https://doi.org/10.1182/blood-2025-2392

Published: 2025

Journal Articles

TSC-101 eliminates recipient hematopoietic cells and demonstrates potential for improved relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT: Updated results from the Phase 1 (ALLOHA) trial

Monzr M. Al Malki, Yi-Bin Chen, Tania Jain, Alla Keyzner, Melhem Solh, Uday Popat, Michele Donato, Luis Pineiro, Hugo Fernandez, Saar Gill, Anson Snow, Joseph Uberti, Timothy White, Yun Wang, Cuong Nguyen, Chrystal Louis, Shrikanta Chattopadhyay, Michelle Matzko, Ran Reshef

Blood (2025) 146 (Supplement 1): 2391.

https://doi.org/10.1182/blood-2025-2391

Published: 2025

Journal Articles

Beyond the unknown: Leveraging machine learning to predict adverse outcomes in pregnant women with aplastic anemia from a representative nationwide cohort

Blood (2025) 146 (Supplement 1): 1413.

https://doi.org/10.1182/blood-2025-1413

Published: 2025

Journal Articles

Can we perform allogeneic hematopoietic cell transplantation (HCT) safely in patients with limited social supports and substantial psychosocial complexity?

Nicolas Trad, Matthew Reynolds, Maya Abdallah, John Mark Sloan, Richard Newcomb, Jennifer D'Alotto, Julie Vanderklish, Nived Subhendu, Michelle Lee, Zachariah Defilipp, Thomas Spitzer, Yi-Bin Chen, Areej El-Jawahri

Blood (2025) 146 (Supplement 1): 4617.

https://doi.org/10.1182/blood-2025-4617

Published: 2025

Journal Articles

Grade I acute graft-vs-host disease: Treat or not?

Blood (2025) 146 (Supplement 1): 2461.

https://doi.org/10.1182/blood-2025-2461

Published: 2025

Journal Articles

The features of FLT3 internal tandem duplication (ITD) in acute myeloid leukemia (AML) patients and impact on prognosis

Bin Chen, Li Wang, Hong Zhang, Yani Lin, Kun Ru

Blood (2025) 146 (Supplement 1): 7017.

https://doi.org/10.1182/blood-2025-7017

Published: 2025

Journal Articles

A mutational grouping involving SRSF2, TET2, ASXL1, RUNX1, and STAG2 identifies patients with lower-risk myelodysplastic syndrome who benefit from higher-risk treatment strategies

Brandon Aubrey, Peter Miller, Timothy Graubert, Yi-Bin Chen, Rohiverth Guarecuco, Amir Fathi, Robert Hasserjian, Andrew Brunner

Blood (2025) 146 (Supplement 1): 2086.

https://doi.org/10.1182/blood-2025-2086

Published: 2025

Journal Articles

Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma

Leon D. Kaulen, Philipp Karschnia, Sofia Doubrovinskaia, Jeremy Abramson, Jacob Soumerai, Maria Martinez-Lage, Julie Haydu, Ganesh Shankar, Chirayu Patel, Bryan D. Choi, Jeffrey Barnes, Areej El-Jawahri, Ephraim Hochberg, Patrick Connor Johnson, Wolfgang Wick, Marcela Maus, Yi-Bin Chen, Matthew Frigault, Jorg Dietrich

Blood (2025) 146 (Supplement 1): 5493.

https://doi.org/10.1182/blood-2025-5493

Published: 2025

Journal Articles

Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia

Blood (2025) 146 (Supplement 1): 6.

https://doi.org/10.1182/blood-2025-6

Published: 2025

Journal Articles

Trials in progress: Design of a registrational Phase 2 trial (ALLOHA) using an external control arm for TSC-101 for prevention of relapse post allogeneic HCT in patients with ALL, AML, or MDS

Blood (2025) 146 (Supplement 1): 2400.

https://doi.org/10.1182/blood-2025-2400

Published: 2025

Journal Articles

The MEASURE Genome Atlas: Acute Myeloid Leukemia at diagnosis and complete remission

Kai Yu, Laura Dillon, Jesse Tettero, Gege Gui, Rasha Al-Ali, Michael Grunwald, Elizabeth Krakow, Elizabeth Griffiths, Alexandra Gomez-Arteaga, Rahul Vedula, Melhem Solh, Amandeep Salhotra, Nelli Bejanyan, Lori Muffly, Antonio Jimenez-Jimenez, Michael Drazer, Yi-Bin Chen, Aaron Logan, Reena Jayani-Kosarzycki, Sophia Balderman, James Blachly, Brian Shaffer, Marc Schwartz, Cecilia Yeung, Lawrence Druhan, Vanessa Kennedy, Sandeep Gurbuxani, Melissa Tjota, Max Smith, Farah Sahoo, Dylan Barfield, Jim Guo, James Han, Jason Hu, Heejoon Jo, Vidya Kudlingar, Wilfred Li, Yutong Qiu, Pratheesh Sathyan, Sean Truong, Severine Catreux, Sam Ng, Khai Luong, Yunjiao Zhu, Reem Bahr, Jamie Diemer, Jianqun Kou, Stephanie Bo-Subait, Jackie Bjerke, Steven Devine, Bergetta Dietel, Christina Ferrone, Gabrielle Giammarino, Emily Heying, Emily Kolb, Danielle O'Donnell Vitali, Wael Saber, Stephen Spellman, Brenna Tesch, Jenny Vogel, Stephanie Waldvogel, Syreeta Weatherspoon, Jeffery Auletta, Christopher Hourigan

Blood (2025) 146 (Supplement 1): 455.

https://doi.org/10.1182/blood-2025-455

Published: 2025

Journal Articles

Orca-T improves chronic graph-versus-host disease free in patients with a broad range of demographic and clinical variables: Results of randomized, Phase 3 trial

Blood (2025) 146 (Supplement 1): 2477.

https://doi.org/10.1182/blood-2025-2477

Published: 2025

Journal Articles

Observational comparison of orca-T to registry-based post-transplant cyclophosphamide patients using matched unrelated donors

Blood (2025) 146 (Supplement 1): 6029.

https://doi.org/10.1182/blood-2025-6029

Published: 2025

Journal Articles

RGI-2001 for the prophylaxis of acute graft-versus-host disease after allogeneic HCT

Zachariah DeFilipp, Hannah Choe, Yvonne A. Efebera, Ayman Saad, Shatha Farhan, Lazaros Lekakis, Jean A. Yared, Gary Schiller, Markus Y. Mapara, Amer Assal, Ted Gooley, Jack D. Bui, Dana Lee, Hayley Lane, Yi-Bin Chen

Blood (2025) 146 (17): 2037–2046.

https://doi.org/10.1182/blood.2025029584

Published: 2025

Includes: Supplemental data

Journal Articles

Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy

Blood (2025) 146 (16): 1902–1913.

https://doi.org/10.1182/blood.2025028964

Published: 2025

Includes: Supplemental data

Journal Articles

Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT

Zachariah DeFilipp, Haesook T. Kim, Laura W. Knight, Suzanne M. O’Connor, Shilton E. Dhaver, Meghan White, Bhagirathbhai Dholaria, Mark A. Schroeder, Sumithira Vasu, Sameem Abedin, Jooho Chung, Areej El-Jawahri, Matthew J. Frigault, Steven McAfee, Richard A. Newcomb, Paul V. O’Donnell, Thomas R. Spitzer, Yi-Bin Chen, Gabriela S. Hobbs

Blood (2025) 145 (20): 2312–2316.

https://doi.org/10.1182/blood.2024028005

Published: 2025

Includes: Supplemental data

Journal Articles

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD –mutated AML

Blood (2025) 145 (19): 2138–2148.

https://doi.org/10.1182/blood.2024025154

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial

Time from AML diagnosis to HCT and pre-HCT FLT3 inhibition impact pre-transplant MRD and benefit from post-HCT gilteritinib

Effect of FLT3 maintenance in older FLT3-ITD+ adults undergoing allogeneic HCT. a post hoc analysis of BMT CTN 1506

Ruxolitinib for refractory immune effector cell enterocolitis following ciltacabtagene autoleucel CAR T-cell therapy for multiple myeloma

TSC-101 eliminates recipient hematopoietic cells and demonstrates potential for improved relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT: Updated results from the Phase 1 (ALLOHA) trial

Beyond the unknown: Leveraging machine learning to predict adverse outcomes in pregnant women with aplastic anemia from a representative nationwide cohort

Can we perform allogeneic hematopoietic cell transplantation (HCT) safely in patients with limited social supports and substantial psychosocial complexity?

Grade I acute graft-vs-host disease: Treat or not?

The features of FLT3 internal tandem duplication (ITD) in acute myeloid leukemia (AML) patients and impact on prognosis

A mutational grouping involving SRSF2, TET2, ASXL1, RUNX1, and STAG2 identifies patients with lower-risk myelodysplastic syndrome who benefit from higher-risk treatment strategies

Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma

Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia

Trials in progress: Design of a registrational Phase 2 trial (ALLOHA) using an external control arm for TSC-101 for prevention of relapse post allogeneic HCT in patients with ALL, AML, or MDS

The MEASURE Genome Atlas: Acute Myeloid Leukemia at diagnosis and complete remission

Orca-T improves chronic graph-versus-host disease free in patients with a broad range of demographic and clinical variables: Results of randomized, Phase 3 trial

Observational comparison of orca-T to registry-based post-transplant cyclophosphamide patients using matched unrelated donors

RGI-2001 for the prophylaxis of acute graft-versus-host disease after allogeneic HCT

Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy

Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD –mutated AML

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only